Do you want to read an article? Please log in or register.
POTOMAC: Durvalumab plus BCG continued to show no OS detriment with no major impact on QoL in BCG-naïve patients with high-risk NMIBC
Genitourinary Cancer
CHICAGO 2026
Related content
ESMO 2025
Genitourinary Cancer
POTOMAC: Durvalumab plus BCG significantly improves DFS in patients with high-risk NMIBC
ESMO 2025
Breast Cancer
monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer
CHICAGO 2025
Gynecologic Cancer
RUBY: Dostarlimab plus carboplatin and paclitaxel shows no detrimental effect on QoL in patients with primary advanced or recurrent endometrial cancer
COMMENTED
Genitourinary Cancer
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Scilipoti P, Zaurito P, Longoni M, Colecchia M, Montorsi F, Salonia A, Mercinelli C, Maiorano B, Necchi A, Briganti A, Moschini M
doi: 10.1016/j.eururo.2025.12.022
ESMO 2025
Breast Cancer
monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer
CHICAGO 2026
Genitourinary Cancer
SAKK 06/19: Intravesical recombinant BCG plus perioperative chemoimmunotherapy shows promising efficacy in patients with MIBC
CHICAGO 2026
Breast Cancer
KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC
CHICAGO 2026
Lymphoma
frontMIND: Adding tafasitamab plus lenalidomide to R-CHOP delays disease progression in patients with high-risk DLBCL
EHA 2025
Multiple Myeloma (MM)